News Industry News Mast Therapeutics Initiates Phase 2 Study Of Vepoloxamer For The Treatment Of Chronic Heart Failure October 26, 2015
News Industry News Juventas Therapeutics Granted FDA Fast Track Designation and Phase 2b Protocol Allowance for Novel Heart Failure Gene Therapy June 16, 2015
News Daily News New CMR-Identified Myocardial Injury Post-TAVR Linked With Decreased LV Function Yael L. Maxwell July 24, 2014